An Australian stem cell and regenerative medicine company

ASX Announcements

13 Dec 2018 NHMRC Funding for Osteoarthritis Trial Using Cymerus MSCs
19 Nov 2018 Cynata Receives $1.3m R&D Tax Incentive Refund
15 Nov 2018 Replacement-Results of Annual General Meeting
15 Nov 2018 Results of Annual General Meeting
15 Nov 2018 Chairman's AGM Address
15 Nov 2018 Annual General Meeting Presentation
07 Nov 2018 CYP Receives Notice of Allowance from European Patent Office
01 Nov 2018 Cynata Clinical Trial Data Accepted for presentation at ASH
01 Nov 2018 Cynata Outlook and Investor Presentation
26 Oct 2018 Appendix 3Y-Dr Paul Wotton
23 Oct 2018 September 2018 Quarterly Report
17 Oct 2018 MSCs Demonstrate Anti-Cancer Effects in Pre-Clinical Studies
11 Oct 2018 Annual Report to Shareholders
11 Oct 2018 Notice of Annual General Meeting/Proxy Form
26 Sep 2018 Notification of 2018 Annual General Meeting Date
25 Sep 2018 Appendix 3Y-Stewart Washer
25 Sep 2018 Appendix 3Y-Dr Ross Macdonald
25 Sep 2018 Appendix 3Y-Dr Paul Wotton
25 Sep 2018 Cleansing Notice
25 Sep 2018 Appendix 3B-Exercise of Options
18 Sep 2018 Cynata MSCs Ameliorate CRS in Preclinical Study
12 Sep 2018 Results of Meeting
05 Sep 2018 Director Loan Funded Shares-Voluntary Escrow Arrangement
03 Sep 2018 Cynata Advances to Official Meeting with Japanese PDMA
31 Aug 2018 Cynata to Present at Rodman & Renshaw Investor Conference
29 Aug 2018 Cynata GvHD Trial Meets all Safety & Efficacy Endpoints
24 Aug 2018 Updated Appendix 4G
22 Aug 2018 Appendix 4G
22 Aug 2018 Appendix 4E & Financial Statements
10 Aug 2018 Notice of General Meeting/Proxy Form
30 Jul 2018 Cymerus MSCs improve cardiac recovery in preclinical study
16 Jul 2018 Cleansing Notice
16 Jul 2018 Appendix 3B-Exercise of Options
11 Jul 2018 Cleansing Notice
11 Jul 2018 Appendix 3B-Exercise of Options
11 Jul 2018 June 2018 Quarterly Report
06 Jul 2018 Cleansing Notice
06 Jul 2018 Appendix 3B-Exercise of Options
01 Jul 2018 Cynata Enters Development Partnership with RCSI
25 Jun 2018 Product Development Program Update & Investor Presentation
20 Jun 2018 Positive 28-day Clinical Trial Data in Cohort B
17 Jun 2018 Research Collaboration with UNSW for Coronary Artery Disease
11 Jun 2018 Positive 6-Month Data from Cohort A in Phase 1 Trial in GvHD
04 Jun 2018 Cleansing Notice
04 Jun 2018 Appendix 3B
30 May 2018 Cynata's MSCs Effective in Model of Diabetic Wounds
29 May 2018 $5.2m placement of shares to Fidelity International
23 May 2018 Enrolment Completed in Cynata's Phase 1 Clinical Trial
22 May 2018 Cleansing Notice
22 May 2018 Appendix 3B-Exercise of Options